NeoGenomics is trading at $14.27 (+6.48%) after reporting a stronger-than-expected second quarter and lifting its full-year guidance.
- The company posted $202 million in revenue, marking 11% year-over-year growth, and a GAAP EPS of $0.02.
- Management raised its 2026 revenue and adjusted EBITDA expectations, signaling confidence in its long-term growth trajectory.
- The stock's performance outpaces the broader healthcare sector (XLV), which is up 2.94% in pre-market trading following positive industry earnings.